OPTIMIZATION OF COMPLEX THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION АND THYROTOXIC CARDIOMYOPATHY

Authors:

Abstract:

The study included 69 patients with stage II arterial hypertension and moderate and severe thyrotoxicosis with thyrotoxic cardiomyopathy. All patients underwent general clinical, laboratory, and instrumental examinations followed by statistical processing of the obtained results. Patients were divided into control and main groups. Patients in the main group were prescribed quercetin in addition to basic and combined antihypertensive therapy. The results of this study prove that the additional use of quercetin has a reliable positive effect on the morpho-functional state of the heart by reducing the size and volume of the left atrium and ventricle, improving the systolic and diastolic function of the myocardium of the left ventricle and regression of hypertrophy with a decrease in the proportion of concentric hypertrophy. The patients also had a stable decrease in heart rate, a significant decrease in the number of extrasystoles, episodes of atrial fibrillation and their duration, an increase in temporal parameters of heart rate variability with normalization of the ratio of spectral indicators, compared to when using only basic therapy. Quercetin should be used as part of complex therapy for patients with arterial hypertension and thyrotoxicosis, with signs of thyrotoxic cardiomyopathy in order to minimize cardiovascular disorders, prevent the progression of structural and functional remodeling of the heart and the occurrence of arrhythmic complications.

Keywords:

arterial hypertension thyrotoxicosis thyrotoxic cardiomyopathy quercetin

References:

1. Marushchak A, Rohovyi Yu, Savchuk T. Zminy prookysno-antyoksydantnoi systemy u shchuriv serii SHR pry likuvanni hipotenzyvnymy preparatamy (ramiprylom i kandesartanom) v kombinatsii z korvitynom. Ukrainskyi naukovo-medychnyi molodizhnyi zhurnal. 2020;115(1):27–36. doi: 10.32345/USMYJ.1(115).2020.27-36. [In Ukrainian]
2. Parkhomenko AN, Kozhukhov SN. Rezultaty otkrytogo randomizirovannogo issledovaniya po izucheniyu perenosimosti i effektivnosti preparata korvitin u patsientov s zastoynoy serdechnoy nedostatochnostyu i sistolicheskoy disfunktsiey levogo zheludochka. Ukrainskyi medychnyi chasopys. 2014;4(102):71–6. Available from: https://www.umj.com.ua/article/78368. [In Russian]
3. Pastukhova OA. Zastosuvannia kvertsetynu v kompleksnomu likuvanni khvorykh na esentsialnu arterialnu hipertenziyu z suputnim tsukrovym diabetom 2-ho typu. Liky Ukrainy. 2015;2:45–48. [In Ukrainian]
4. Solomenchuk TM, Prokosa MI, Klymkovych OIu. Znyzhennia ryzyku nedosiahnennia kontroliu arterialnoho tysku v patsiientiv z arterialnoiu hipertenziieiu ta ishemichnoiu khvoroboiu sertsia: rol kvertsetynu. Patolohiya. 2023;1(20):14–19. doi: 10.14739/2310-1237.2023.1.268435. [In Ukrainian]
5. Shved NI, Prokopovich EA, Geryak SN, Dobryanskaya VYu. Effektivnost bioflavonoidov i RNK-soderzhaschikh preparatov v kompleksnom lechenii bolnykh infarktom miokarda s narusheniem funktsionalnogo sostoyaniya pecheni. Vrachebnoe delo. 2018;1,2:46–55. doi: 10.31640/JVD.1-2.2018(08). [In Russian]
6. Abdel-Moneim A, Gaber AM, Gouda S, Osama A, Othman SI, Allam G. Relationship of thyroid dysfunction with cardiovascular diseases: updated review on heart failure progression. Hormones (Athens). 2020;19(3):301–309. doi: 10.1007/s42000-020-00208-8.
7. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. European Heart Journal. 2012;33(21):2719–47. doi: 10.1093/eurheartj/ehs253.
8. Doubleday AR, Sippel RS. Hyperthyroidism. Gland Surgery. 2020;9(1):124–35. doi: 10.21037/gs.2019.11.01.
9. Khan R, Sikanderkhel S, Gui J, Adeniyi AR, O’Dell K, Erickson M, et al. Thyroid and Cardiovascular Disease: A Focused Review on the Impact of Hyperthyroidism in Heart Failure. Cardiology Research. 2020;11(2):68–75. doi: 10.14740/cr1034.
10. Molinaro G, De Vecchis R, Badolati E, Giannattasio R. Thyrotoxic dilated cardiomyopathy: personal experience and case collection from the literature. Endocrinology Diabetes and Metabolism Case Reports. 2020;24.2020:20-0068. doi: 10.1530/EDM-20-0068.
11. Omotosho YB, Farooqi A, Bakar A, Jeelani H. Thyrotoxicosis: A Primary Cause of Arrhythmias and Acute Heart Failure. Journal of the Endocrine Society. 2021;5(1): A967. doi: 10.1210/jendso/bvab048.1976.
12. Salehi B, Machin L, Monzote L, Sharifi-Rad J, Ezzat SM, Salem MA, et al. Therapeutic Potential of Quercetin: New Insights and Perspectives for Human Health. ACS Omega. 2020;5(20):11849–72. doi: 10.1021/acsomega.Oc01818.
13. Sharma A, Stan MN. Thyrotoxicosis: Diagnosis and Management. Mayo Clinic Proceedings. 2019;94(6):1048–64. doi: 10.1016/j.mayocp.2018.10.011.
14. Vale C, Neves JS, von Hafe M, Borges-Canha M, Leite-Moreira A. The Role of Thyroid Hormones in Heart Failure. Cardiovasc Drugs Ther. 2019;33(2):179–188. doi: 10.1007/s10557-019-06870-4.
15. Wiersinga WM, Poppe KG, Effraimidis G. Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis. Lancet Diabetes Endocrinol. 2023;11(4):282–298. doi: 10.1016/S2213-8587(23)00005-0.

Publication:

«World of Medicine and Biology» Vol. 19 No. 85 (2023) , с. 175-179
УДК 616.12-008.331.1:616.441-002-08

DOI:

https://doi.org/10.26724/2079-8334-2023-3-85-175-179